No connection

Search Results

ACON vs HCWB

ACON
Aclarion, Inc.
BEARISH
Price
$3.33
Market Cap
$3.5M
Sector
Healthcare
AI Confidence
92%
HCWB
HCW Biologics Inc.
BEARISH
Price
$0.36
Market Cap
$2.5M
Sector
Healthcare
AI Confidence
98%

Valuation

P/E Ratio
ACON
--
HCWB
--
Forward P/E
ACON
-0.24
HCWB
-0.66
P/B Ratio
ACON
0.16
HCWB
-0.45
P/S Ratio
ACON
52.03
HCWB
45.26
EV/EBITDA
ACON
1.38
HCWB
-0.58

Profitability

Gross Margin
ACON
-7.83%
HCWB
20.0%
Operating Margin
ACON
-9666.16%
HCWB
-18370.3%
Profit Margin
ACON
0.0%
HCWB
0.0%
ROE
ACON
-97.72%
HCWB
--
ROA
ACON
-52.37%
HCWB
-31.19%

Growth

Revenue Growth
ACON
31.5%
HCWB
-93.2%
Earnings Growth
ACON
--
HCWB
--

Financial Health

Debt/Equity
ACON
--
HCWB
2.46
Current Ratio
ACON
17.01
HCWB
0.11
Quick Ratio
ACON
16.31
HCWB
0.09

Dividends

Dividend Yield
ACON
--
HCWB
--
Payout Ratio
ACON
0.0%
HCWB
0.0%

AI Verdict

ACON BEARISH

ACON's deterministic health scores are severely compromised: the Piotroski F-Score of 1/9 signals extreme financial distress, and the absence of an Altman Z-Score (with negative profitability and liquidity anomalies) raises serious bankruptcy concerns. Despite a 31.5% YoY revenue growth, the company exhibits catastrophic profitability—negative gross, operating, and ROE margins—indicating fundamental operational failure. The stock trades at a price/sales of 52.03, vastly exceeding peers and suggesting extreme overvaluation relative to earnings. Analysts' target price of $23.00 is not supported by fundamentals, and insider activity remains neutral with no recent trades. The 5-year price decline of 100% underscores deep investor skepticism.

Strengths
31.5% year-over-year revenue growth indicates top-line expansion
High current and quick ratios (17.01 and 16.31) suggest strong short-term liquidity
Recent 1-month price increase (+22.9%) shows short-term momentum
Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and poor operational health
Negative operating margin (-9666.16%) and ROE (-97.72%) reflect systemic profitability collapse
Price/Sales of 52.03 is unsustainable and far exceeds peer averages (avg: ~185.39 P/E, but negative margins suggest no valid comparison)
HCWB BEARISH

HCWB exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.11 and a catastrophic revenue collapse of -93.20% YoY. With a negative Price-to-Book ratio (-0.45) and an operating margin of -18370.31%, the firm is effectively eroding its remaining capital. The stock's 96% decline over the past year reflects a market pricing in a high probability of insolvency.

Strengths
Positive Gross Margin (20%)
Single analyst target price ($2.00) suggests theoretical upside
Recent 1-week short-term price bounce (+36%)
Risks
Extreme liquidity risk (Current Ratio 0.11)
Catastrophic revenue decline (-93.20% YoY)
Negative shareholder equity (Price/Book -0.45)

Compare Another Pair

ACON vs HCWB: Head-to-Head Comparison

This page compares Aclarion, Inc. (ACON) and HCW Biologics Inc. (HCWB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile